Concern has been raised about the effectiveness of the coronavirus disease 2019 (COVID-19) vaccine in the population of patients with various comorbidities such as heart disease. We investigated the humoral response to the BNT162b2 mRNA COVID-19 vaccine in patients with cardiovascular disease (CVD). We measured IgG against severe acute respiratory syndrome coronavirus 2 spike receptor-binding domain (RBD-IgG) in 85 CVD patients and 179 healthcare workers (HCWs). Blood samples were collected from patients and HCWs three times: (1) before the first dose of vaccination, (2) two weeks after the first dose of vaccination, and (3) two weeks after the second dose of vaccination. Patients with CVD showed a significantly inferior serological response to the BNT162b2 mRNA COVID-19 vaccine at 14 days after the prime dose compared to HCWs (21% vs. 95%, p < 0.001). Median RBD-IgG titers of patients with CVD at 14 days after the second dose were significantly lower than those of HCWs (137.2 U/mL (80.6–200.4 U/mL) vs. 176.2 U/mL (123.9–260.0 U/mL), p < 0.001). In multivariable analyses, CVD is significantly associated with seropositivity after first vaccination and RBD-IgG titers after second vaccination. CVD patients may have a poor humoral response to the BNT162b2 mRNA COVID-19 vaccine, need to be closely monitored, and require earlier revaccination to ensure stronger immunity and protection against infection.
【저자키워드】 Vaccine, immunogenicity, cardiovascular disease, Coronavirus disease 2019 (COVID-19), 【초록키워드】 COVID-19, coronavirus disease, IgG, coronavirus, COVID-19 vaccine, vaccination, Immunity, Infection, Comorbidity, healthcare worker, HCWs, Patient, Effectiveness, spike receptor-binding domain, concern, disease, BNT162b2 mRNA, serological response, dose, humoral, HCW, CVD, acute respiratory syndrome, second vaccination, second dose, first dose, blood sample, revaccination, multivariable analyses, first vaccination, significantly lower, collected, significantly, investigated, raised, 【제목키워드】 COVID-19, cardiovascular, mRNA, of BNT162b2,